A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
The bicinchoninic acid assay (BCA assay), also known as the Smith assay, after its inventor, Paul K. Smith at the Pierce Chemical Company, is a biochemical assay for determining the total concentration of protein in a solution (0.5 μg/mL to 1.5 mg/mL), similar to Lowry protein assay, Bradford protein assay or biuret reagent. The total protein concentration is exhibited by a color change of the sample solution from blue to purple in proportion to protein concentration, which can then be measured using colorimetric techniques. The BCA assay was patented by Pierce Chemical Company in 1989 & the patent expired in 2006.
The ability of an ice road to safely support the weight of a vehicle, or any other loads applied onto it, referred to as bearing capacity, is the primary concern when designing, building and using that structure. Generally speaking, a vertically loaded ice cover will react in two ways: 1) it will sink, and 2) it will bend in flexure. In order to meet the ice bearing criteria, the top surface should not sink below the water line and the applied flexural stress should not exceed the ice's flexural strength. Three loading regimes have to be considered: a) maximum weight for standard usage or for parking during a short duration; b) a load that remains stationary during an extensive time period; and c) dynamic loading of the ice cover, from a traveling vehicle.
These latter amino acids are therefore termed "ketogenic" amino acids, whereas those that enter the citric acid cycle as intermediates can only be cataplerotically removed by entering the gluconeogenic pathway via malate which is transported out of the mitochondrion to be converted into cytosolic oxaloacetate and ultimately into glucose. These are the so-called "glucogenic" amino acids. De-aminated alanine, cysteine, glycine, serine, and threonine are converted to pyruvate and can consequently either enter the citric acid cycle as oxaloacetate (an anaplerotic reaction) or as acetyl-CoA to be disposed of as CO2 and water. In fat catabolism, triglycerides are hydrolyzed to break them into fatty acids and glycerol. In the liver the glycerol can be converted into glucose via dihydroxyacetone phosphate and glyceraldehyde-3-phosphate by way of gluconeogenesis. In skeletal muscle, glycerol is used in glycolysis by converting glycerol into glycerol-3-phosphate, then into dihydroxyacetone phosphate (DHAP), then into glyceraldehyde-3-phosphate. In many tissues, especially heart and skeletal muscle tissue, fatty acids are broken down through a process known as beta oxidation, which results in the production of mitochondrial acetyl-CoA, which can be used in the citric acid cycle. Beta oxidation of fatty acids with an odd number of methylene bridges produces propionyl-CoA, which is then converted into succinyl-CoA and fed into the citric acid cycle as an anaplerotic intermediate.
== Related compounds == A dual DOR and κ-opioid receptor (KOR) PAM, BMS-986187, derived from BMS-986122, has been developed and is selective for these receptors over the MOR. Another MOR PAM with a simpler synthesis, MS1, was subsequently developed and has shown similar effects to those of BMS-986122. Additionally, ignavine, a natural MOR PAM found in Aconitum, has also been identified. In 2024, ketamine and its metabolites norketamine and hydroxynorketamine (HNK) were identified as highly potent MOR, DOR, and KOR PAMs (active at a concentration of as low as 1 nM). These actions were implicated in their potential antidepressant and analgesic effects.
Sources: en.wikipedia.org
=== Androgen deficiency === Primary hypogonadism (indicating an intrinsic problem with the testes in males) leads to decreased testosterone synthesis and increased conversion of testosterone to estradiol, potentially leading to a gynecomastic appearance. Klinefelter syndrome is a notable example of a disorder that causes hypogonadism and gynecomastia, and has a higher risk of breast cancer in males (20–50 times higher than males without the disorder). Secondary hypogonadism (indicating a problem with the brain) leads to decreased production and release of luteinizing hormone (LH, a stimulatory signal for endogenous steroid hormone synthesis) which leads to decreased production of testosterone and estradiol in the testes.
=== Sclerodactyly === Though it is the most easily recognizable manifestation, it is not prominent in all patients. Thickening generally only involves the skin of the fingers distal to the metacarpophalangeal joints in CREST. Early in the course of the disease, the skin may appear edematous and inflamed. Eventually, dermal fibroblasts overproduce extracellular matrix leading to increased tissue collagen deposition in the skin. Collagen cross-linking then causes a progressive skin tightening. Digital ischemic ulcers commonly form on the distal fingers in 30–50% of patients.
In 1980 the FDA removed the dwarfism indication from the label for stanozolol since human growth hormone drugs had come on the market, and mandated that the label for stanozolol and other steroids say: "As adjunctive therapy in senile and postmenopausal osteoporosis. AAS are without value as primary therapy but may be of value as adjunctive therapy. Equal or greater consideration should be given to diet, calcium balance, physiotherapy, and good general health promoting measures." and gave Sterling a timeline to submit further data for other indications it wanted for the drug. Sterling submitted data to the FDA intended to support the effectiveness of Winstrol for postmenopausal osteoporosis and aplastic anemia in December, 1980 and August 1983 respectively. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee considered the data submitted for osteoporosis in two meetings held 1981 and the data for aplastic anemia in 1983. In April 1984, the FDA announced that the data was not sufficient, and withdrew the marketing authority for stanozolol for senile and postmenopausal osteoporosis and for raising hemoglobin levels in aplastic anemia. In 1988, Sterling was acquired by Eastman Kodak for $5.1 billion and in 1994 Kodak sold the drug business of Sterling to Sanofi for $1.675 billion. Sanofi had stanozolol manufactured in the US by Searle, which stopped making the drug in October 2002. Even with no drug in production, Sanofi sold the stanozolol business to Ovation Pharmaceuticals in 2003, along with the two other drugs.
Sources: en.wikipedia.org
=== December === 6 December Scientists, for the first time, report a recently discovered area on the current planet Earth, particularly in the Puna de Atacama territory of South America, which may be similar to ancient Earth, and the related environment of the first life forms on Earth – as well as – similar to possibly hospitable conditions on the planet Mars during earlier Martian times. Google DeepMind announces its Gemini multimodal language model, which it claims has advanced "reasoning capabilities" and can outperform GPT-4 on a variety of tasks. 7 December A gene therapy based on three transcription factors, Oct4, Sox2, and Klf4 (OSK), is shown to provide sustained vision recovery in mice affected by glaucoma. Physicists report future proposed plans for the next ten years. These proposals are intended to help better understand some of the current concerns of particle physics, including challenges to the Standard Model, and involve studies primarily dealing with gravity, black holes, dark matter, dark energy, Higgs boson, muons, neutrinos, and more. Quantum entanglement of molecules is achieved for the first time. A comprehensive review of ancient carbon dioxide levels and corresponding temperatures is published by a consortium of more than 80 researchers from 16 nations. Their study finds that current levels of atmospheric carbon dioxide are the highest in at least 14 million years, much longer ago than some existing assessments indicate.
=== Insects === Order Blattodea Blattella germanica, German cockroach (2018) Periplaneta americana, American cockroach (2018) Zootermopsis nevadensis, a dampwood termite (2014 Cryptotermes secundus, a drywood termite(2018) Macrotermes natalensis, a higher termite (2014 Order Coleoptera Dendroctonus ponderosae Hopkins, beetle (mountain pine beetle) (2013) Aquatica lateralis, Japanese aquatic firefly "Heike-botaru" (firefly) (2018) Photinus pyralis, Big Dipper firefly (2018) Protaetia brevitarsis, White-spotted flower chafer (2019) Tribolium castaneum Strain:GA-2, beetle (red flour beetle) (2008) Allomyrina dichotoma, Japanese rhinoceros beetle (2022) Pachyrhynchus sulphureomaculatus, Easter Egg Weevil (2021) Order Collembola Family Isotomidae Desoria tigrina, (2021) Family Sminthurididae Sminthurides aquaticus, (2021) Order Diptera Family Calliphoridae Aldrichina grahami, Forensic blowfly (2020) Family Chironomidae Dasypogon diadema, Hunting Robber fly (2019) Parochlus steinend, Antarctic winged midge (2017) Proctacanthus coquilletti, Assassin fly (2017) Family Culicidae (mosquitoes) Aedes aegypti Strain:LVPib12, mosquito (vector of dengue fever, etc.) (2007) Aedes albopictus (2015) Anopheles darlingi Anopheles gambiae Strain: PEST, mosquito (vector of malaria) (2002) Anopheles gambiae Strain: M, mosquito (vector of malaria) (2010) Anopheles gambiae Strain: S, mosquito (vector of malaria) (2010) Anopheles sinensis, mosquito (vector of vivax malaria, lymphatic filariasis and Setaria infections), (2014) Anopheles stephensii Anopheles arabiensis (2015) Anopheles quadriannulatus (2015) Anopheles merus (2015) Anopheles melas (2015) Anopheles christyi (2015) Anopheles epiroticus (2015) Anopheles maculatus (2015) Anopheles culicifacies (2015) Anopheles minimus (2015) Anopheles funestus (2015, 2019) Anopheles dirus (2015) Anopheles farauti (2015) Anopheles atroparvus (2015) Anopheles sinensis (2015) Anopheles albimanus (2015) Culex quinquefasciatus, mosquito (vector of West Nile virus, filariasis etc.) (2010) Family Drosophilidae (fruit flies) Drosophila albomicans, fruit fly (2012) Drosophila ananassae, fruit fly (2007) Drosophila biarmipes, fruit fly (2011) Drosophila bipectinata, fruit fly (2011) Drosophila erecta, fruit fly (2007) Drosophila elegans, fruit fly (2011) Drosophila eugracilis, fruit fly (2011) Drosophila ficusphila, fruit fly (2011) Drosophila grimshawi, fruit fly (2007) Drosophila kikkawai, fruit fly (2011) Drosophila melanogaster, fruit fly (model organism) (2000) Drosophila mojavensis, fruit fly (2007) Drosophila neotestacea, fruit fly (transcriptome 2014) Drosophila persimilis, fruit fly (2007) Drosophila pseudoobscura, fruit fly (2005) Drosophila rhopaloa, fruit fly (2011) Drosophila santomea, fruit fly () Drosophila sechellia, fruit fly (2007) Drosophila simulans, fruit fly (2007) Drosophila takahashi, fruit fly (2011) Drosophila virilis, fruit fly (2007) Drosophila willistoni, fruit fly (2007) Drosophila yakuba, fruit fly (2007) Family Phoridae Megaselia abdita, scuttle fly (transcriptome 2013) Family Psychodidae (drain flies) Clogmia albipunctata, moth midge (transcriptome 2013) Family Sarcophagidae (flesh flies) Sarcophaga Bullata, Flesh fly (2019) Family Syrphidae (hoverflies) Episyrphus balteatus, hoverfly (transcriptome 2011) Order Hemiptera Acyrthosiphon pisum, aphid (pea aphid) (2010) Ericerus pela, Chinese wax scale insect (2019) Laodelphax striatellus, small brown planthopper (2017) Lycorma delicatula, spotted lanternfly (2019) Rhodnius prolixus, kissing-bug (2015) Rhopalosiphum maidis, Corn leaf aphid (2019) Sitobion miscanthi, Indian grain aphid (2019) Triatoma rubrofasciata, assassin bug (2019) Order Hymenoptera Acromyrmex echinatior colony Ae372, ant (Panamanian leafcutter) (2011) Apis mellifera, bee (honey bee), (model for eusocial behavior) (2006) Atta cephalotes, ant (leaf-cutter ant) (2011) Camponotus floridanus, ant (2010) Cerapachys biroi, ant (clonal raider ant)(2014) Euglossa dilemma, Green orchid bee (2017) Harpegnathos saltator, ant (2010) Lasius niger, ant (black garden ant)(2017) Linepithema humile, ant (Argentine ant) (2011) Nasonia giraulti, wasp (parasitoid wasp) (2010) Nasonia longicornis, wasp (parasitoid wasp) (2010) Nasonia vitripennis, wasp (parasitoid wasp; model organism) (2010) Netelia fuscicornis, wasp (parasitoid wasp) (2024) Nomia Melanderi, Alkali bee (2019) Pogonomyrmex barbatus, ant (red harvester ant) (2011) Solenopsis invicta, ant (fire ant) (2011) Order Lepidoptera Abrostola tripartita Hufnagel, Spectacle (2021) Achalarus lyciades, Hoary Edge Skipper (2017) Ahamus jianchuanensis, Jianchuan ghost moth (2024) Antharaea yamamai, Japanese oak silk moth (2019) Arctia plantaginis, Wood tiger moth (2020) Bicyclus anynana, squinting bush brown (2017) Bombyx mori Strain:p50T, moth (domestic silk worm) (2004) Calycopis cecrops, Red-Banded Groundstreak (2016) Calycopis isobeon, Dusky-Blue Groundstreak (2016) Coenonympha arcania, Pearly Heath (2024) Cydia pomonella, codling moth (2019) Danaus plexippus, monarch butterfly) (2011) Erebia cassioides, Common Brassy Ringlet (2025) Heliconius melpomene, butterfly (2012) Keiferia lycopersicella, Tomato pinworm (2024) Melitaea cinxia, Glanville fritillary butterfly (2014) Megathymus ursus violae, bear giant skipper butterfly (2018) Morpho helenor, Common blue morpho (2023) Morpho achilles, Blue-banded morpho (2023) Morpho deidamia (2023) Papilio bianor, Chinese peacock butterfly (2019) Phthorimaea absoluta, Tomato leafminer (2024) Pieris rapae, small cabbage white butterfly (2016) Plodia interpunctella, Indianmeal moth (2022) Plutella xylostella, moth (diamondback moth) (2013) Scrobipalpa atriplicella, Goosefoot groundling moth (2024) Spodoptera frugiperda, Fall armyworm (2017) Thitarodes armoricanus, Himalaya ghost moth (2024) Thitarodes xiaojinensis, Xiaojin ghost moth (2024) Troides aeacus, Golden birdwing (2024) Eudocima phalonia, fruit-piercing moth (2017) Order Orthoptera Locusta migratoria, migratory locust (2014) Schistocerca gregaria, desert locust (2020) Gryllus bimaculatus, two-spotted cricket (2021) Order Phthiraptera Pediculus humanus, louse (sucking louse; parasite) (2010) Menopon gallinae, Poutlry shaft louse (2024) Psocoptera Liposcelis brunnea, booklouse (2022) Order Raphidioptera Venustoraphidia nigricollis, black-necked snakefly (2023) Order Trichoptera Eubasilissa regina, purple caddisfly (2022,) Stenopsyche tienmushanensisi, Caddisfly (2018) Order Mantodea Tenodera sinensis, chinese praying mantis (2023)
== Further reading == Nakagawa, Allen S., LIMS implementation and management, Cambridge: Royal Society of Chemistry, 1994 Liscouski, Joe, Laboratory and Scientific Computing a Strategic Approach, John Wiley & Sons, New York, 1995 Gibbon, Gerst, "A Brief History of LIMS", Laboratory Automation and Information Management 1996, 32(1), 1-5 Myers, J. D.; Fox-Dobbs, C.; Laird, J.; Le, Dai; Reich, D.; Curtz, T., "Electronic laboratory notebooks for collaborative research", In Proceedings of the 5th International Workshops on Enabling Technologies: Infrastructure for Collaborative Enterprises (WET ICE'96) (WET-ICE '96) IEEE Computer Society, Washington, DC, USA, 1996, 47-. Paszko, Christine; Pugsley, Carol, "Considerations in selecting a laboratory information management system (LIMS)", American Laboratory, 2000, 32(18), 38-42 Paszko, Christine; Turner, Elizabeth; Hinton, Mary D., Laboratory Information Management Systems, Revised & Expanded.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.